KCT0009472招募中Unknown
Effects, safety, and study feasibility of Gamisoyo-san on dysmenorrhea patients with premenstrual syndrome: a randomized, open, usual care-controlled, feasibility clinical trial
Daejeon Korean Medicine Hospital of Daejeon University0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- Female
入选标准
- •1) Female aged 19 to 45 years.
- •2) Participants who have consistently experienced primary dysmenorrhea (menstrual pain) in the past three months, with a Visual Analogue Scale (VAS) score of 40 mm or higher.
- •3) Participants who have consistently experienced premenstrual syndrome over the past three months and meet the following criteria during the most recent menstrual cycle at the time of Visit 1 and one menstrual cycle during the screening period:
- •-Meet the diagnostic criteria for premenstrual syndrome by the American College of Obstetricians and Gynecologists (ACOG).
- •-Score at or above the threshold for moderate to severe PMS on the Premenstrual Symptoms Screening Tool (PSST).
- •4) Participants with a regular menstrual cycle ranging from 21 to 35 days (28±7 days) over the past three months.
- •5) Participants who have voluntarily given written consent to participate in the clinical trial.
排除标准
- •1) Participants with a history of major psychiatric disorders within the past two years, those currently taking psychotropic medications such as antidepressants, or those suspected of having major depressive disorder, panic disorder, generalized anxiety disorder, bulimia nervosa, binge-eating disorder, or alcohol use disorder based on the Patient Health Questionnaire (PHQ).
- •2) Those who have taken oral contraceptives or undergone female hormone therapy within the last three months, or those who have taken products containing Agnus Castus or traditional herbal medicines for menstrual pain and premenstrual syndrome within one month prior to screening.
- •3) Participants diagnosed with intra-pelvic lesions such as uterine fibroids, adenomyosis, endometriosis, or pelvic inflammatory disease.
- •4) Those with thyroid diseases or abnormal thyroid function test results at screening (TSH = 0.6 µIU/ml or TSH = 6.8 µIU/ml).
- •5) Participants currently using an intrauterine device.
- •6) Pregnant or breastfeeding participants, or those not using a medically acceptable method of contraception during the trial.
- •7) Participants with severe liver or kidney disorders, or those with AST, ALT = twice the upper limit of normal, BUN = twice the upper limit of normal, or Creatinine = 2.0 mg/dl at screening.
- •8) Those diagnosed with a malignant tumor within the past five years.
- •9) Participants with a hemoglobin level less than 11 g/dL at screening or diagnosed with and treated for anemia.
- •10) Those with uncontrolled hypertension (systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mmHg at screening).
- •11) Participants with uncontrolled diabetes (HbA1c = 9% or fasting glucose = 160 mg/dL at screening).
- •12) Those with uncontrolled serious systemic diseases including cardiovascular, respiratory, gastrointestinal, genitourinary, neurological/psychiatric, hematological disorders, endocrine disorders (e.g., hyperprolactinemia), autoimmune diseases (e.g., systemic lupus erythematosus), or severe infectious diseases.
- •13) Participants with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
- •14) Participants with known hypersensitivity to the investigational medicinal product.
- •15) Those who have participated in another clinical trial and received an investigational drug within three months prior to the screening visit.
- •16) Participants who don't record the dysmenorrhea symptom diary or whose menstrual pain VAS score is less than 40 mm preceding the baseline visit.
- •17) Participants deemed unable to participate in the clinical trial for other reasons.
研究者
相似试验
招募中
4 期
A real-world study of the safety and efficacy of Ganmaoling granules (999) in the treatment of the common coldcommon coldITMCTR2000002998China-Japan Friendship Hospital
招募中
Unknown
Efficacy, Safety and Economic Evaluation of Gamidaeganghwal-tang for Degenerative Knee Osteoarthritis : A multicenter, randomized, double-blind, parallel clinical trialKCT0008486Kyung Hee University Oriental Medicine Hospital at Gangdong240
未知
2 期
A prospective exploratory study on the safety of gastric endoscopic submucosal dissection without cessation of warfarin.The lesion that is indicated in gastric endoscopic submucosal dissection in patients who use warfarin for prevention of thrombosis.JPRN-UMIN000020850The University of Tokyo Hospital Department of Gastroenterology, Graduate School of Medicine15
尚未招募
4 期
Evaluation of Gamma-oryzanol in Type-2 diabetesCTRI/2020/06/026007AP Organics
进行中（未招募）
1 期
A study about adjusting the dose of the anticancer drugs fluoropyrimindes based on mutations in DNA (genetic code)Types of cancer for which capecitabine and 5-fluorouracil are authorized, this includes colorectal cancer, gastric cancer and locally advanced or metastatic breast cancerEUCTR2014-005064-15-NLetherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-ALV)1,250